Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease

European Journal of Neurology

Volumn 20, Issue 2, 2013, Pages 271-280

  Schapira, A H V ^a   Stocchi, F ^b   Borgohain, R ^c   Onofrj, M ^d   Bhatt, M ^e   Lorenzana, P ^f   Lucini, V ^g   Giuliani, R ^g   Anand, R ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^d UNIVERSITY OF CHIETI   (Italy)

^e Kokilaben Dhiruben Ambani Hospital   (India)

^f UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^g Newron Pharmaceuticals Spa   (Italy)

^h APC AG   (Switzerland)

Author keywords

aminoamide; Add on; Dopamine agonist; Parkinson's disease; Safinamide

Indexed keywords

BROMOCRIPTINE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SAFINAMIDE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BACKACHE; BLURRED VISION; CATARACT; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTRITIS; HUMAN; HYPERTENSION; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PARKINSON DISEASE; PARKINSONISM; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCOTOMA; TACHYCARDIA; TIME; UPPER ABDOMINAL PAIN; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ALANINE; ANTIPARKINSON AGENTS; BENZYLAMINES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EARLY MEDICAL INTERVENTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84872367500     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03840.x     Document Type: Article

References (30)

1. Schapira AH. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci 2009; 30: 41-47.
2. Schapira AH. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007; 64: 1083-1088.
3. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006; 59: 559-562.
4. Schapira AH, Olanow CW. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol 2008; 64(Suppl. 2): S47-S55.
5. Schapira AH. Future directions in the treatment of Parkinson's disease. Mov Disord 2007; 22(Suppl. 17): S385-S391.
6. Binda C, Wang J, Pisani L, et al. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007; 50: 5848-5852.
7. Marzo A, Del Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004; 50: 77-85.
8. Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006; 67(7 Suppl. 2): S18-S23.
9. Caccia C, Salvati P, Rossetti S, Anand R. Safinamide: modulation of dopaminergic and glutamaterfic systems. Mov Disord 2008; 23: S22-S23.
10. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother 2010; 11: 2261-2268.
11. Schapira AH, Borgohain R, Stocchi F, et al. Long-term safety and efficacy of safinamide added to dopamine agonists in early Parkinson's disease (PD). Neurology 2008; 70(11 Suppl. 1): A424.
12. Anand R, Onofrj M, Schapira AH, Rossetti S. Safinamide potentiates the effects of DA-agonists in early stage Parkinson's disease (PD) patients. Mov Disord 2007; 22(Suppl. 16): 797.
13. Borgohain R, Bhatt M, Rossetti S, Anand R. Safinamide potentiates the effects of dopamine (DA)-agonists in early stage Parkinson's disease patients. Parkinsonism Relat Disord 2007; 13(Suppl. 2): S99.
14. Stocchi F, Borgohain R, Onofrj M, et al. Safinamide, a new anti-Parkinson agent is effective and well-tolerated in early PD Patients on a stable dose of a single DA-agonist: results of a randomized, international, placebo-controlled Phase III trial. Neurology 2007; 12(Suppl. 1): A109, abs S20.001.
15. Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord 2012; 27: 106-112.
16. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55(Suppl. 1): 23-30.
17. Bonuccelli U, Pavese N. Dopamine agonists in the treatment of Parkinson's disease. Expert Rev Neurother 2006; 6: 81-89.
18. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044-1053.
19. Poewe W, Antonini A, Zijlmans JCM, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interventions Aging 2010; 5: 229-238.
20. Stocchi F, Arnold G, Onofrj M, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004; 63: 746-748.
21. Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006; 67(7 Suppl. 2): S24-S29.
22. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol 2006; 13: 1186-1202.
23. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society - European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006; 13: 1170-1185.
24. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-520.
25. Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson's disease. Mol Neurobiol 1996; 12: 73-94.
26. Blandini F. An update on the potential role of excitotoxicity in the pathogenesis of Parkinson's disease. Funct Neurol 2010; 25: 65-71.
27. Nandhu MS, Paul J, Kuruvila KP, Abraham PM, Antony S, Paulose CS. Glutamate and NMDA receptors activation leads to cerebellar dysfunction and impaired motor coordination in unilateral 6-hydroxydopamine lesioned Parkinson's rat: functional recovery with bone marrow cells, serotonin and GABA. Mol Cell Biochem 2011; 353: 47-57.
28. Pevarello P, Bonsignori A, Dostert P, et al. Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives. J Med Chem 1998; 41: 579-590.
29. Caccia C, Salvati P, Rossetti S, Anand R. Safinamide: beyond MAO-B inhibition. Parkinsonism Relat Disord 2007; 13(Suppl. 2): S99.
30. Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs 2007; 8: 570-579.